Lee & Man Chemical (SEHK:746) Margin Rebound Challenges Long Term Earnings Decline Narrative

Lee & Man Chemical (SEHK:746) has released its FY 2025 first half numbers, reporting revenue of HK$1,931.9 million and basic EPS of HK$0.40, with investors weighing these results against a trailing twelve month EPS of HK$0.68. The company has seen half year revenue shift from HK$1,989.7 million in 1H 2024 and HK$1,961.1 million in 2H 2024 to HK$1,931.9 million in 1H 2025. EPS moved from HK$0.29 in each half of FY 2024 to HK$0.40 in the latest period, highlighting a narrative that now focuses on how sustainably its margins have firmed.

See our full analysis for Lee & Man Chemical.

With the headline numbers on the table, the next step is to set them against the prevailing market narratives and assess whether the recent margin performance supports or challenges what investors already believe about Lee & Man Chemical.

Curious how numbers become stories that shape markets? Explore Community Narratives

Margins Backed By HK$326.6 Million Half Year Profit

• Net income for 1H FY 2025 was HK$326.6 million on revenue of HK$1,931.9 million, which lines up with the trailing twelve month net profit margin of 14.9% compared with 12.2% a year earlier.
• Supporters of a more positive view point to this 14.9% margin and 15.8% earnings growth over the last year, yet the data also shows earnings falling at an average rate of 17.6% per year over five years,
  • That mix of a stronger recent year but weaker five year trend means the improved 1H FY 2025 margin sits against a longer history of earnings pressure.
  • For you as an investor, it is a prompt to look at whether the current HK$326.6 million half year profit feels like a stable base or something that has moved around over time.

TTM EPS Of HK$0.68 Versus Prior Weak Multi Year Trend

• Trailing twelve month basic EPS sits at HK$0.68, with the most recent half year at roughly HK$0.40 compared with around HK$0.29 in each half of FY 2024, alongside 15.8% earnings growth over the last year against a five year earnings decline of 17.6% per year.
• Bears highlight that long term 17.6% per year earnings decline as a key risk, and the current HK$0.68 trailing EPS and stronger 14.9% margin mainly challenge that cautious view at the one year mark rather than across the full period,
  • The fact that trailing earnings improved over the last year while the five year average still points to declines suggests the business has had periods of weaker profitability that long term focused investors will likely keep in mind.
  • If you are wondering how to weigh this, the recent EPS level gives some support to short term improvement while the longer history keeps the risk of further profit swings on the table.

On the back of this mix of a stronger trailing twelve months and a weaker five year record, it can help to see what other investors are saying about how durable they think these profits are, so 📊 Read the what the Community is saying about Lee & Man Chemical.

P/E Of 7.9x And Large Gap To DCF Fair Value

• At a share price of HK$5.35, the stock trades on a 7.9x trailing P/E, above the 6.7x peer average but below the Hong Kong chemicals industry average of 10.7x, while the DCF fair value is HK$11.57, which is materially higher than the current price.
• What stands out for valuation focused investors is the tension between the DCF fair value of HK$11.57 and the history of earnings falling 17.6% per year over five years,
  • The 14.9% net margin and 15.8% earnings growth in the last year sit on the supportive side of that DCF view, because they are stronger than the prior year figures.
  • At the same time, the stock being slightly more expensive than peers on P/E while carrying that multi year earnings decline means some investors may still treat the apparent discount to DCF with caution.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Lee & Man Chemical's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

Curious whether the balance of positives and concerns here really lines up with your own expectations? Act while the details are fresh and stress test the thesis against the company specific risks and rewards by checking out 1 key reward and 2 important warning signs.

See What Else Is Out There

The mix of a weaker five year earnings trend, cautious margin history and only middling P/E relative to peers leaves plenty of questions around consistency.

If you want to balance that patchy record with ideas that emphasise steadier profiles and clearer downside protection, check out our 301 resilient stocks with low risk scores that focus on companies with more resilient overall risk scores right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com